<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37433880</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1759-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Nature reviews. Rheumatology</Title><ISOAbbreviation>Nat Rev Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Towards a novel clinical outcome assessment for systemic lupus erythematosus: first outcomes of an international taskforce.</ArticleTitle><Pagination><StartPage>592</StartPage><EndPage>602</EndPage><MedlinePgn>592-602</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41584-023-00993-7</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a disease of high unmet therapeutic need. The challenge of accurately measuring clinically meaningful responses to treatment has hindered progress towards positive outcomes in SLE trials, impeding the approval of potential new therapies. Current primary end points used in SLE trials are based on legacy disease activity measures that were neither specifically designed for the clinical trial context, nor developed according to contemporary recommendations for clinical outcome assessments (COAs), such as that substantial patient input should be incorporated into their design. The Treatment Response Measure for SLE (TRM-SLE) Taskforce is a global collaboration of SLE clinician-academics, patients and patient representatives, industry partners and regulatory experts, established to realize the goal of developing a new COA for SLE clinical trials. The aim of this project is a novel COA designed specifically to measure treatment effects that are clinically meaningful to patients and clinicians, and intended for implementation in a trial end point that supports regulatory approval of novel therapeutic agents in SLE. This Consensus Statement reports the first outcomes of the TRM-SLE project, including a structured process for TRM-SLE development.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Connelly</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-1332-5050</Identifier><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia. kathryn.connelly@monash.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eades</LastName><ForeName>Laura E</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koelmeyer</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayton</LastName><ForeName>Darshini</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golder</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandane-Rathnayake</LastName><ForeName>Rangi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Kate</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunner</LastName><ForeName>Hermine</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-9478-2987</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Cincinnati Children's Hospital, University of Cincinnati, Cincinatti, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burke</LastName><ForeName>Laurie</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>LORA Group, Royal Oak, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnaud</LastName><ForeName>Laurent</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8077-8394</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, National Reference Center for Autoimmune Diseases (RESO), Hopitaux Universitaires de Strasbourg, Strasbourg, Alsace, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lupus Center, Columbia University Medical Center, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranow</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lupus Centre of Excellence, Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vital</LastName><ForeName>Ed</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-1637-4755</Identifier><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pons-Estel</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Centro Regional de Enfermedades Autoinmunes y Reum&#xe1;ticas de Grupo Oro&#xf1;o (GO CREAR), Rosario, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dantata</LastName><ForeName>Khadija</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Lupus Foundation of America, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-8848-9039</Identifier><AffiliationInfo><Affiliation>Lupus Europe, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornet</LastName><ForeName>Alain</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Lupus Europe, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buie</LastName><ForeName>Joy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lupus Foundation of America, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Merck Healthcare KGaA, Darmstadt, Hesse, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanaka</LastName><ForeName>Yoshiya</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0807-7139</Identifier><AffiliationInfo><Affiliation>The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Lee</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>SDG LLC, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lahoud</LastName><ForeName>Youmna</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-5677-3665</Identifier><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Friedman</LastName><ForeName>Alan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AbbVie, Libertyville, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalunian</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Immunology, University of California, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zuraw</LastName><ForeName>Qing</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Janssen Research and Development, Spring House, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Werth</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garces</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Amgen, Thousand Oaks, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morand</LastName><ForeName>Eric F</ForeName><Initials>EF</Initials><Identifier Source="ORCID">0000-0002-9507-3338</Identifier><AffiliationInfo><Affiliation>School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>TRM-SLE Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Nat Rev Rheumatol</MedlineTA><NlmUniqueID>101500080</NlmUniqueID><ISSNLinking>1759-4790</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barbey</LastName><ForeName>Catherine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karis</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morand</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noss</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Md Smith</LastName><ForeName>Eve</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stojan</LastName><ForeName>George</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Teres</LastName><ForeName>Jorge Ross</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Maller</LastName><ForeName>Justine</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hojnik</LastName><ForeName>Maya</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delev</LastName><ForeName>Nikolay</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eades</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dall'Era</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marquis</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Furie</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Vollenhoven</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Coulom</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sibley</LastName><ForeName>Cailin</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stach</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vazquez-Mateo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zollars</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guay</LastName><ForeName>Heath</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Mossawi</LastName><ForeName>Hussein</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Merrill</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terres</LastName><ForeName>Jorge Ross</ForeName><Initials>JR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Costenbader</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Silk</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mosca</LastName><ForeName>Marta</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Nicki</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Subhashis</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sornasse</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rubio</LastName><ForeName>Blanca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tremarias</LastName><ForeName>Dalila</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kalla</LastName><ForeName>Dalilah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carrizo</LastName><ForeName>Gonzalo Tobar</ForeName><Initials>GT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adisa</LastName><ForeName>Imasha</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagamori</LastName><ForeName>Shiori</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Komati</LastName><ForeName>Sibongile</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scoggins</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gydesen</LastName><ForeName>Susanne Udengaard</ForeName><Initials>SU</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grimes</LastName><ForeName>Toni</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haroun</LastName><ForeName>Vinita</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karakikla-Mitsa</LastName><ForeName>Zoe</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eldred</LastName><ForeName>Ann</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fedriz</LastName><ForeName>Bianca</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lindholm</LastName><ForeName>Catharine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lupton</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grasela</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Juarez</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Nitin</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Guenther</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pomponi</LastName><ForeName>Samantha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roy</LastName><ForeName>Sanjeev</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kafka</LastName><ForeName>Shelly</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morel</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pincus</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>12</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>11</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37433880</ArticleId><ArticleId IdType="doi">10.1038/s41584-023-00993-7</ArticleId><ArticleId IdType="pii">10.1038/s41584-023-00993-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kandane-Rathnayake, R. et al. &#x2018;Not at target&#x2019;: prevalence and consequences of inadequate disease control in systemic lupus erythematosus &#x2014; a multinational observational cohort study. Arthritis Res. Ther. 24, 70 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-022-02756-3</ArticleId><ArticleId IdType="pubmed">35287720</ArticleId><ArticleId IdType="pmc">8919535</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmeding, A. &amp; Schneider, M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best. Pract. Res. Clin. Rheumatol. 27, 363&#x2013;375 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2013.07.009</ArticleId><ArticleId IdType="pubmed">24238693</ArticleId></ArticleIdList></Reference><Reference><Citation>Yen, E. Y. &amp; Singh, R. R. Brief report: lupus &#x2014; an unrecognized leading cause of death in young females: a population-based study using nationwide death certificates, 2000&#x2013;2015. Arthritis Rheumatol. 70, 1251&#x2013;1255 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40512</ArticleId><ArticleId IdType="pubmed">29671279</ArticleId><ArticleId IdType="pmc">6105528</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill, J. T. et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci. Med. 5, e000258 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000258</ArticleId><ArticleId IdType="pubmed">29657738</ArticleId><ArticleId IdType="pmc">5894527</ArticleId></ArticleIdList></Reference><Reference><Citation>Connelly, K., Golder, V., Kandane-Rathnayake, R. &amp; Morand, E. Clinician-reported outcome measures in lupus trials: a problem worth solving. Lancet Rheumatol. 3, e595&#x2013;e603 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00119-3</ArticleId></ArticleIdList></Reference><Reference><Citation>US Department of Health and Human Services Food and Drug Administration. Patient-Focused Drug Development Guidance Series for Enhancing the Incorporation of the Patient&#x2019;s Voice in Medical Product Development and Regulatory Decision Making. Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments (Draft Guidance). https://www.fda.gov/media/159500/download (2022).</Citation></Reference><Reference><Citation>Powers, J. H. 3rd et al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health 20, 2&#x2013;14 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jval.2016.11.005</ArticleId><ArticleId IdType="pubmed">28212963</ArticleId><ArticleId IdType="pmc">5379997</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. F. et al. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet 392, 1330&#x2013;1339 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)32167-6</ArticleId><ArticleId IdType="pubmed">30249507</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace, D. J. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 392, 222&#x2013;231 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(18)31363-1</ArticleId><ArticleId IdType="pubmed">30043749</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. F. et al. Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. Ann. Rheum. Dis. 81, 1556&#x2013;1563 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222858</ArticleId><ArticleId IdType="pubmed">35798534</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I). Lancet 401, 1001&#x2013;1010 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02607-1</ArticleId><ArticleId IdType="pubmed">36848918</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri, M. et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet 401, 1011&#x2013;1019 (2023).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)02546-6</ArticleId><ArticleId IdType="pubmed">36848919</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie, R. et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol. 1, E208&#x2013;E219 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30076-1</ArticleId></ArticleIdList></Reference><Reference><Citation>Morand, E. F. et al. Trial of anifrolumab in active systemic lupus erythematosus. N. Engl. J. Med. 382, 211&#x2013;221 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1912196</ArticleId><ArticleId IdType="pubmed">31851795</ArticleId></ArticleIdList></Reference><Reference><Citation>Oon, S., Huq, M., Godfrey, T. &amp; Nikpour, M. Systematic review, and meta-analysis of steroid-sparing effect, of biologic agents in randomized, placebo-controlled phase 3 trials for systemic lupus erythematosus. Semin. Arthritis Rheum. 48, 221&#x2013;239 (2018).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.01.001</ArticleId><ArticleId IdType="pubmed">29426575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce, I. N. et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann. Rheum. Dis. 81, 962&#x2013;969 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-221847</ArticleId><ArticleId IdType="pubmed">35580976</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunner, H. I. et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann. Rheum. Dis. 79, 1340&#x2013;1348 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217101</ArticleId><ArticleId IdType="pubmed">32699034</ArticleId></ArticleIdList></Reference><Reference><Citation>Maxwell, L. J. et al. Core domain set selection according to OMERACT filter 2.1: the OMERACT methodology. J. Rheumatol. 46, 1014&#x2013;1020 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.181097</ArticleId><ArticleId IdType="pubmed">30770502</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn, K. et al. Definition and initial validation of a Lupus low disease activity state (LLDAS). Ann. Rheum. Dis. 75, 1615&#x2013;1621 (2016).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>van Vollenhoven, R. F. et al. 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci. Med. https://doi.org/10.1136/lupus-2021-000538 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2021-000538</ArticleId><ArticleId IdType="pubmed">34930819</ArticleId><ArticleId IdType="pmc">8689160</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>